Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

Clin Infect Dis. 2005 Jun 1;40(11):1601-7. doi: 10.1086/429914. Epub 2005 Apr 28.


Background: Telavancin, a novel lipoglycopeptide, exerts concentration-dependent, rapid bactericidal activity on account of its multiple mechanisms of action. Telavancin is highly active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate, and vancomycin-resistant strains.

Methods: We conducted a randomized, double-blind, controlled, phase-2 clinical trial. Patients > or = 18 years of age with a diagnosis of complicated skin and soft-tissue infection caused by suspected or confirmed gram-positive organisms were randomized to receive either intravenously administered telavancin once daily or standard therapy (antistaphylococcal penicillin 4 times daily or vancomycin twice daily).

Results: For the study, 167 patients were randomized and received at least 1 dose of study medication. Success rates were similar in all analysis populations at the test-of-cure evaluation. Of patients with S. aureus infection at baseline (n = 102), 80% of the telavancin group were cured and 77% of the standard therapy group were cured. For patients with MRSA infection at baseline (n = 48), cure rates were 82% for the telavancin group and 69% for the standard therapy group. Microbiologic eradication in patients with MRSA infection was 84% for the telavancin group versus 74% for the standard therapy group. MIC90 values were lower for telavancin in all tested strains of S. aureus (< or = 0.25 ug/mL) compared with the MIC90 values for vancomycin and oxacillin. Similar proportions of patients discontinued therapy for adverse events in both treatment groups (approximately 5%). Fewer serious adverse events were reported in the telavancin group (4 events) than were for the standard therapy group (9).

Conclusion: Clinical and microbiological results of this study support the further development of telavancin, especially for treatment of infection due to MRSA.

Publication types

  • Clinical Trial, Phase II
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aminoglycosides / adverse effects
  • Aminoglycosides / therapeutic use*
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use*
  • Double-Blind Method
  • Female
  • Gram-Positive Bacterial Infections / drug therapy*
  • Gram-Positive Bacterial Infections / microbiology
  • Humans
  • Lipoglycopeptides
  • Male
  • Middle Aged
  • Penicillins / adverse effects
  • Penicillins / therapeutic use
  • Skin Diseases, Bacterial / drug therapy*
  • Skin Diseases, Bacterial / microbiology*
  • Soft Tissue Infections / drug therapy*
  • Soft Tissue Infections / microbiology*
  • Vancomycin / adverse effects
  • Vancomycin / therapeutic use


  • Aminoglycosides
  • Anti-Bacterial Agents
  • Lipoglycopeptides
  • Penicillins
  • Vancomycin
  • telavancin